Cannabis Stocks Rally on Reports of Trump Marijuana Reclassification
Tilray shares hit their highest level since October, extending a rally driven by anticipation of President Trump’s potential cannabis reclassification order.
Fact Check
The statement is strongly supported by a consensus across multiple high-authority and highly relevant sources. Financial news outlets like Barron's and Proactive Investors explicitly and directly report that cannabis stocks, such as Tilray and Canopy Growth, surged in price following the news that the Trump administration was considering reclassifying marijuana. This core claim is corroborated by other credible sources, including CNBC, industry publications like MJBizDaily, and even a legal analysis from a law firm, all of which confirm both the administration's consideration of reclassification and the subsequent positive reaction in stock prices. There is no conflicting evidence among the provided sources. The consistency and high authority of the primary sources make the statement very likely to be true.
Summary
Tilray Brands’ stock reached its highest price since October 20, continuing a sharp rally fueled by speculation that President Donald Trump may issue an executive order to reclassify marijuana. The move follows a previous 28% surge in Tilray shares, part of a broader uptick in cannabis-related stocks amid growing investor optimism over regulatory changes.
Terms & Concepts
- Marijuana Reclassification: A change in how marijuana is classified under federal law, which can impact legality, regulation, and business operations.
- Tilray: A Canada-based pharmaceutical and cannabis company producing and distributing cannabis products internationally.
- Cannabis Stocks: Publicly traded shares of companies involved in the cultivation, distribution, or sale of cannabis products.